Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aperture-collimated proton LATTICE radiotherapy with a GRID-like entrance pattern: a compact and robust delivery strategy.

Physics in medicine and biology·2026
Same author

Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas.

Neuro-oncology·2026
Same author

Advancing Particle Therapy to Improve Cancer Care: Report on "2nd World Forum on Particle Therapy".

International journal of particle therapy·2026
Same author

A pig model of human radiation-induced veno-occlusive liver disease reveals ferroptosis as a therapeutic target.

Cell reports. Medicine·2026
Same author

TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma.

Neuro-oncology·2026
Same author

Clinical Implementation of Simulation-Free Palliative Radiation Therapy: Consensus Recommendations From a Modified Delphi Study.

Advances in radiation oncology·2026

Related Experiment Video

Updated: May 29, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Hepatic radiation toxicity: avoidance and amelioration.

Chandan Guha1, Brian D Kavanagh

  • 1Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. cguha@montefiore.org

Seminars in Radiation Oncology
|September 24, 2011
PubMed
Summary

Radiation-induced liver disease (RILD) awareness is crucial for refining radiation therapy. Minimizing liver dose and sparing critical volumes can reduce RILD risk, especially in vulnerable patients.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
04:53

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

Published on: August 25, 2022

Related Experiment Videos

Last Updated: May 29, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
04:53

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

Published on: August 25, 2022

Area of Science:

  • Hepatology
  • Radiation Oncology
  • Medical Physics

Background:

  • Advancements in radiation therapy and radioembolization have renewed interest in radiation-induced liver disease (RILD).
  • Understanding factors influencing RILD is vital for patient selection and minimizing toxicity.
  • Classic RILD presents with ascites and hepatomegaly, typically occurring after a mean liver dose of ~30 Gy in conventional fractionation.

Purpose of the Study:

  • To review the clinical and technical parameters influencing radiation-induced liver disease (RILD).
  • To discuss strategies for minimizing RILD risk in patients undergoing radiation therapy.
  • To explore potential therapeutic interventions for RILD.

Main Methods:

  • Review of current literature on radiation-induced liver disease (RILD).
  • Analysis of technical parameters (e.g., dose, critical volume sparing) in radiation therapy.
  • Examination of clinical factors (e.g., pre-existing liver disease, hepatocellular carcinoma) impacting RILD susceptibility.
  • Exploration of preclinical and clinical data on potential RILD mitigation strategies.

Main Results:

  • Stereotactic delivery techniques enable higher tumor doses by maintaining low mean liver doses and sparing critical liver volumes.
  • Patients with hepatocellular carcinoma or pre-existing liver disease (Child-Pugh B/C) are more susceptible to RILD, potentially with nonclassic presentations.
  • No pharmacologic interventions are currently proven to mitigate RILD, but preclinical research shows promise for TGF-β inhibitors and cell transplantation.
  • Fibrinolytic and antithrombotic agents used for veno-occlusive liver disease suggest a potential role in managing RILD.

Conclusions:

  • Minimizing mean liver dose and sparing critical liver volumes are key to reducing RILD risk with modern radiation techniques.
  • Vigilance is required for high-risk patient groups, including those with hepatocellular carcinoma or compromised liver function.
  • Further research into targeted therapies and regenerative medicine holds potential for future RILD management.